Kolon TissueGene (950160), which had plunged due to uncertainties surrounding its U.S. clinical trials, is rebounding in the morning session on the 27th.

Although it started on a weak note immediately after the market open, it quickly recouped its losses and expanded its gains. The stock opened at 15,530 won and fell to 14,800 won as selling pressure emerged. However, buying interest soon flowed in, driving a rebound that lifted the price to as high as 15,890 won intraday, recovering more than 7% from the session low.

As of 9:05 a.m., Kolon TissueGene is trading at 15,680 won, up 4.53% from the previous trading day. If this trend holds, it will mark a shift to an upward trajectory for the first time in seven trading days.

Given the significant short-term correction from the recent consecutive declines, the rebound is interpreted as a growing perception that the drop was excessive, coupled with some bargain-hunting demand. However, since it is still early in the session, it remains to be seen whether the current upward momentum will be sustained until the close. In particular, it is difficult to rule out the possibility that this rebound is of a technical nature following a steep decline, rather than being driven by the resolution of clinical uncertainties.

Key factors that will determine the stock's future direction include the company's updates on clinical progress, additional explanations, and changes in supply and demand. Kolon TissueGene has recently been reacting sensitively to clinical-related news, leading to heightened volatility. Rather than concluding a trend reversal based solely on a short-term rebound, it is necessary to also monitor trading volume, the closing price, and any additional disclosures.

[This article was written based on intraday market prices and does not recommend the purchase or sale of any specific stock. Stock prices may fluctuate further during the session, and all investment decisions and responsibilities lie with the investor. This article was written with AI assistance.]